55503-06-5Relevant academic research and scientific papers
Polycyclic compound for inhibiting RNA helicase DHX33
-
Paragraph 0217-0220, (2021/04/17)
The invention relates to a polycyclic compound for inhibiting RNA helicase DHX33. In particular, the invention relates to a compound shown as a formula I or a pharmaceutically acceptable form thereof, a pharmaceutical composition containing the compound, a preparation method of the compound, and medical application of the compound to prevention and/or treatment of DHX33 related diseases.
Synthesis of novel 5-chlorinated 2-aminothiophenes using 2,5-dimethylpyrrole as an amine protecting group
Puterova, Zita,Bobula, Tomas,Vegh, Daniel
, p. 201 - 207 (2008/09/18)
(Chemical Equation Presented) A new synthetic methodology towards substituted 2-amino-5-chlorothiophenes is described. Compounds of this type are important as building blocks for oligomers used in polymer research. Easily available 2-aminothiophenes underwent Paal-Knorr reaction to protect the free amino group before electrophilic substitution. Although the chlorination was predicted to proceed at the thiophene ring, only free positions of 2,5-dimethylpyrrole were substituted. To direct chlorination to the thiophene ring acetamido derivative was prepared first and then chlorinated. Transamination with hexane-2,5-dione created a 2,5-dimethyl pyrrole ring from the acetamido group. In the final step, after treatment with hydroxylamine dihydrochloride, the pyrrole ring is removed and a free amino group is regenerated.
NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
-
Page/Page column 38, (2008/06/13)
The present invention encompasses compounds of Formula (I) as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dysliptdemias and the like. Pharmaceutical compositions and methods of use are also
Thienopyridine-carboxylic acid derivatives
-
, (2008/06/13)
Novel thienopyridine-carboxylic acid derivatives, which are shown by the general formula SPC1 Wherein R1 represents hydrogen or a lower alkyl; R2 represents hydrogen, a lower alkyl or a halogen; or R1 and R2, taken together, may represent an alkylene to form a 5- or 6-membered ring with or without alkyl substituents; each of R4 and R5 represents hydrogen or a lower alkyl; and their pharmaceutically acceptable salts obtainable when R4 is hydrogen, which are useful medicines such as chemotherapeutic agents of bacterial infections.
